Osteoporosis - Pipeline Review, H1 2020

Publisher Name :
Date: 30-Apr-2020
No. of pages: 353
Inquire Before Buying

Osteoporosis - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 8, 7, 22, 4, 63, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Osteoporosis - Pipeline Review, H1 2020

Table of Contents
Introduction
Osteoporosis - Overview
Osteoporosis - Therapeutics Development
Osteoporosis - Therapeutics Assessment
Osteoporosis - Companies Involved in Therapeutics Development
Osteoporosis - Drug Profiles
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Osteoporosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Osteoporosis - Pipeline by Ablynx NV, H1 2020
Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2020
Osteoporosis - Pipeline by Addpharma Inc, H1 2020
Osteoporosis - Pipeline by Aerami Therapeutics, H1 2020
Osteoporosis - Pipeline by Affilogic SAS, H1 2020
Osteoporosis - Pipeline by AgeX Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by AlphaMab Co Ltd, H1 2020
Osteoporosis - Pipeline by Altum Pharmaceuticals Inc, H1 2020
Osteoporosis - Pipeline by Amgen Inc, H1 2020
Osteoporosis - Pipeline by Aryogen Pharmed Co, H1 2020
Osteoporosis - Pipeline by Axsome Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Bainan Biotech ApS, H1 2020
Osteoporosis - Pipeline by BIOCND Inc, H1 2020
Osteoporosis - Pipeline by Biosion Inc, H1 2020
Osteoporosis - Pipeline by Bone Biologics Corp, H1 2020
Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2020
Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
Osteoporosis - Pipeline by Corium, Inc., H1 2020
Osteoporosis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
Osteoporosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Eli Lilly and Co, H1 2020
Osteoporosis - Pipeline by EndoCeutics Inc, H1 2020
Osteoporosis - Pipeline by Enesi Pharma Ltd, H1 2020
Osteoporosis - Pipeline by Entera Bio Ltd, H1 2020
Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2020
Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2020
Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2020
Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2020
Osteoporosis - Pipeline by Galapagos NV, H1 2020
Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by GlycoNex Inc, H1 2020
Osteoporosis - Pipeline by GPN Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2020
Osteoporosis - Pipeline by Helixmith Co Ltd, H1 2020
Osteoporosis - Pipeline by Hengenix Biotech Inc, H1 2020
Osteoporosis - Pipeline by Histide AG, H1 2020
Osteoporosis - Pipeline by HNB Therapeutics LLC, H1 2020
Osteoporosis - Pipeline by Hualan Biological Engineering Inc, H1 2020
Osteoporosis - Pipeline by Huons Co Ltd, H1 2020
Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2020
Osteoporosis - Pipeline by IMGENEX India Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Immunwork Inc, H1 2020
Osteoporosis - Pipeline by InnoPharmaScreen Inc, H1 2020
Osteoporosis - Pipeline by Innovent Biologics Inc, H1 2020
Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2020
Osteoporosis - Pipeline by Ipsen SA, H1 2020
Osteoporosis - Pipeline by JHL Biotech Inc, H1 2020
Osteoporosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Osteoporosis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Keros Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Kolmar Pharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Kyoto Pharmaceutical Industries Ltd, H1 2020
Osteoporosis - Pipeline by LBL Biotech Corp, H1 2020
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2020
Osteoporosis - Pipeline by Lupin Ltd, H1 2020
Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2020
Osteoporosis - Pipeline by Max Biopharma Inc, H1 2020
Osteoporosis - Pipeline by Merck & Co Inc, H1 2020
Osteoporosis - Pipeline by Mesentech Inc, H1 2020
Osteoporosis - Pipeline by Metabolab Inc, H1 2020
Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Nano Intelligent Biomedical Engineering Corp, H1 2020
Osteoporosis - Pipeline by Nanomedic Inc, H1 2020
Osteoporosis - Pipeline by NeuClone Pty Ltd, H1 2020
Osteoporosis - Pipeline by NovMetaPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Omeros Corp, H1 2020
Osteoporosis - Pipeline by Ortho Regenics Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2020
Osteoporosis - Pipeline by Pfenex Inc, H1 2020
Osteoporosis - Pipeline by PhytoHealth Corp, H1 2020
Osteoporosis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by R Pharm, H1 2020
Osteoporosis - Pipeline by Regenerative Arthritis & Bone Medicine Inc, H1 2020
Osteoporosis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Ribomic Inc, H1 2020
Osteoporosis - Pipeline by Sandoz International GmbH, H1 2020
Osteoporosis - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Junshi Bioscience Co Ltd, H1 2020
Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by Shin Poong Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Suzhou Stainwei Biotech Inc, H1 2020
Osteoporosis - Pipeline by Taithera Inc, H1 2020
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
Osteoporosis - Pipeline by Tritech Biopharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2020
Osteoporosis - Pipeline by USV Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Vibe Pharmaceuticals LLC, H1 2020
Osteoporosis - Pipeline by Vidasym Inc, H1 2020
Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Zosano Pharma Corp, H1 2020
Osteoporosis - Dormant Projects, H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..3), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..4), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..5), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..6), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..7), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..8), H1 2020
Osteoporosis - Discontinued Products, H1 2020
Osteoporosis - Discontinued Products, H1 2020 (Contd..1), H1 2020



List of Figures
Number of Products under Development for Osteoporosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
  • Global Raloxifene Hydrochloride Market Research Report 2020 (Covid-19 Version)
    Published: 09-Jul-2020        Price: US 3500 Onwards        Pages: 137
    Summary Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Tablet - Capsule By Application - Pharmaceuticals - Chemicals - Others By Company - Eli Lilly and Company - InvaGen Pharmaceuticals Inc - Actavis - Cadila Pharmaceuticals Ltd. - Zydus Alidac......
  • COVID-19 Outbreak-Global Raloxifene Hydrochloride Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
    Published: 07-Jul-2020        Price: US 3660 Onwards        Pages: 125
    Raloxifene hydrochloride is an oral medication intended for the prevention of osteoporosis in postmenopausal women. In addition, raloxifene hydrochloride medications are also used for the reduction of risk and treatment of invasive breast cancer. The Raloxifene Hydrochloride market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under COVID-19 outbreak globally, this report provides 360 degrees of analys......
  • COVID-19 Outbreak-Global Osteoporosis Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
    Published: 30-Jun-2020        Price: US 3660 Onwards        Pages: 111
    The osteoporosis drug is a kind of drug that can be used to treat osteoporosis. The Osteoporosis Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterp......
  • COVID-19 Impact on Global Raloxifene Hydrochloride Market Insights, Forecast to 2026
    Published: 16-Jun-2020        Price: US 3900 Onwards        Pages: 118
    Raloxifene Hydrochloride market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Raloxifene Hydrochloride market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026. Segment by Type, the Raloxifene Hydrochloride market is segmented into - Tablet Dosage Form - Other ......
  • COVID-19 Impact on Global Zoledronic Acid Market Insights, Forecast to 2026
    Published: 16-Jun-2020        Price: US 3900 Onwards        Pages: 115
    Zoledronic Acid market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Zoledronic Acid market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026. Segment by Type, the Zoledronic Acid market is segmented into - Injection - Powder Segment by Application, the......
  • 2015-2027 Global Risedronate Sodium Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
    Published: 09-Jun-2020        Price: US 2960 Onwards        Pages: 111
    The worldwide market for Risedronate Sodium is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach X.X million US$ in 2027, from X.X million US$ in 2020. The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in Major Regions, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, by type, application and marketing channel. In addition, the report focuses on the driving......
  • Covid-19 Impact on 2021-2026 Global and Regional Alendronate Sodium Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report Standard Version
    Published: 08-Jun-2020        Price: US 3500 Onwards        Pages: 159
    The research team projects that the Alendronate Sodium market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026. The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. D......
  • 2015-2027 Global Alendronate Sodium Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
    Published: 02-Jun-2020        Price: US 2960 Onwards        Pages: 104
    The worldwide market for Alendronate Sodium is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach X.X million US$ in 2027, from X.X million US$ in 2020. The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in Major Regions, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, by type, application and marketing channel. In addition, the report focuses on the driving......
  • Raloxifene Hydrochloride Market Research: Global Status & Forecast by Geography, Type & Application (2016-2026)
    Published: 26-May-2020        Price: US 2280 Onwards        Pages: 58
    Summary According to 99Strategy, the Global Raloxifene Hydrochloride Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Raloxifene Hydrochloride market, the market size and growth, as well as the major market participants. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, th......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs